Compare Stocks → Protect Yourself While There’s Still Time … (From Weiss Ratings) (Ad) Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS). Comparison Ideas Agriculture StocksAirline StocksApparel StocksArtificial Intelligence StocksAutomotive StocksBank StocksBitcoin StocksBlockchain StocksCanadian StocksCannabis StocksCasino StocksChatGPT StocksChinese StocksCloud Storage StocksCoronavirus Therapeutics StocksCryptocurrency StocksCybersecurity StocksDefense StocksDividend StocksDow 30 StocksEcommerce StocksElectric Vehicles StocksEnergy StocksEntertainment StockseSports StocksEV Charging StocksFertilizer StocksGold StocksGrocery StocksGrowth StocksHealthcare StocksHigh Dividend StocksHome Office StocksHotel StocksLarge Cap StocksLeisure StocksLithium StocksMagnificent Seven StocksMATANA StocksMega Cap StocksMeme StocksMetaverse StocksMid Cap StocksMining StocksMusic Industry StocksNanotechnology StocksNFT StocksOil StocksOutdoor Activities StocksPharmaceutical StocksRenewable Energy StocksRestaurant StocksRetail StocksSemiconductor StocksSocial Media StocksSolar StocksSpace StocksStay-At-Home StocksTechnology StocksTelecom StocksToy StocksUtility StocksVaccine StocksVideo Game StocksVirtual Reality StocksWallStreetBets Stocks Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare Share Comparison Share Comparison NASDAQ:GERNNASDAQ:MRUSNASDAQ:TXMDNASDAQ:XENENASDAQ:ZFGN Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Stocks - Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeGERNGeron$3.79+6.5%$2.86$1.64▼$4.05$2.07B0.6211.07 million shs7.87 million shsMRUSMerus$45.04+0.2%$45.05$18.21▼$52.03$2.64B1.1595,155 shs822,958 shsTXMDTherapeuticsMD$1.88+0.5%$2.22$1.86▼$4.73$21.68M1.0320,942 shs6,212 shsXENEXenon Pharmaceuticals$40.50+1.0%$44.12$27.99▼$50.99$3.05B1.15398,124 shs320,772 shsZFGNZafgen$6.44+1.7%$18.47$0.62▼$2.76$241.31M0.27360,199 shs144,013 shs12 Stocks Corporate Insiders are AbandoningIf a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know?Get This Free ReportPrice PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceGERNGeron-0.56%-4.56%+7.88%+64.81%+46.50%MRUSMerus+7.05%+11.02%+0.04%+31.99%+126.80%TXMDTherapeuticsMD-2.60%-1.58%-16.89%-17.62%-47.03%XENEXenon Pharmaceuticals+1.52%-0.52%-6.00%-12.14%+1.47%ZFGNZafgen-2.01%-0.78%-12.08%+33.83%+40.35%Protect Yourself While There’s Still Time … (Ad)The next step of the Fed's control is here. Section 702 of the Foreign Intelligence Surveillance Act was renewed for two more years and passed into law earlier this week. Allowing the Fed to tighten its grip on your personal privacy and freedom.4 simple steps to protect your privacy and money before it’s too late.MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationGERNGeron2.9314 of 5 stars3.51.00.01.31.81.70.6MRUSMerus2.4323 of 5 stars4.52.00.00.01.81.70.0TXMDTherapeuticsMDN/AN/AN/AN/AN/AN/AN/AN/AXENEXenon Pharmaceuticals2.6426 of 5 stars3.54.00.00.02.62.50.0ZFGNZafgenN/AN/AN/AN/AN/AN/AN/AN/AAnalyst RatingsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceGERNGeron3.00Buy$5.3340.72% UpsideMRUSMerus3.00Buy$56.3325.07% UpsideTXMDTherapeuticsMD2.00HoldN/AN/AXENEXenon Pharmaceuticals3.00Buy$59.4446.78% UpsideZFGNZafgenN/AN/AN/AN/ACurrent Analyst RatingsLatest MRUS, ZFGN, GERN, XENE, and TXMD Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/22/2024MRUSMerusWilliam BlairSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform4/12/2024XENEXenon PharmaceuticalsNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$62.004/11/2024GERNGeronNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$5.004/11/2024MRUSMerusNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$66.004/10/2024GERNGeronWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform ➝ Outperform$6.004/10/2024XENEXenon PharmaceuticalsCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOverweight ➝ Overweight$65.003/28/2024MRUSMerusTruist FinancialSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$69.003/15/2024GERNGeronWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform ➝ Outperform$6.003/15/2024GERNGeronThe Goldman Sachs GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$4.00 ➝ $5.003/15/2024GERNGeronNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$4.00 ➝ $5.003/4/2024MRUSMerusNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$42.00 ➝ $65.00(Data available from 4/26/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookGERNGeron$240K8,635.99N/AN/A$0.46 per share8.24MRUSMerus$43.95M60.15N/AN/A$6.17 per share7.30TXMDTherapeuticsMD$1.30M16.67N/AN/A$2.77 per share0.68XENEXenon Pharmaceuticals$9.43M323.96N/AN/A$14.18 per share2.86ZFGNZafgenN/AN/AN/AN/A$1.35 per shareN/AProfitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateGERNGeron-$184.13M-$0.33N/AN/AN/A-77,691.14%-63.33%-44.71%5/2/2024 (Confirmed)MRUSMerus-$154.94M-$3.04N/AN/AN/A-352.56%-50.61%-37.56%5/2/2024 (Estimated)TXMDTherapeuticsMD-$10.28MN/A0.00∞N/AN/A-25.54%-14.87%5/20/2024 (Estimated)XENEXenon Pharmaceuticals-$182.39M-$2.72N/AN/AN/AN/A-25.18%-23.99%5/14/2024 (Estimated)ZFGNZafgen-$45.41M-$1.07N/A∞N/AN/A-51.34%-34.55%N/ALatest MRUS, ZFGN, GERN, XENE, and TXMD EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/2/2024N/AGERNGeron-$0.10N/A+$0.10N/AN/AN/A 2/29/2024Q4 2023XENEXenon Pharmaceuticals-$0.76-$0.64+$0.12-$0.64$2.30 millionN/A 2/28/2024Q4 23GERNGeron-$0.10-$0.09+$0.01-$0.09$0.06 million$0.02 million 2/28/2024Q4 2023MRUSMerus-$0.71-$1.09-$0.38-$1.09$10.43 million$8.94 millionDividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthGERNGeronN/AN/AN/AN/AN/AMRUSMerusN/AN/AN/AN/AN/ATXMDTherapeuticsMDN/AN/AN/AN/AN/AXENEXenon PharmaceuticalsN/AN/AN/AN/AN/AZFGNZafgenN/AN/AN/AN/AN/ADebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioGERNGeron0.143.163.16MRUSMerusN/A5.345.34TXMDTherapeuticsMDN/A1.721.72XENEXenon PharmaceuticalsN/A23.6523.65ZFGNZafgen0.266.566.56OwnershipInstitutional OwnershipCompanyInstitutional OwnershipGERNGeron73.71%MRUSMerus96.14%TXMDTherapeuticsMD30.74%XENEXenon Pharmaceuticals95.45%ZFGNZafgen70.43%Insider OwnershipCompanyInsider OwnershipGERNGeron3.10%MRUSMerus4.30%TXMDTherapeuticsMD1.20%XENEXenon Pharmaceuticals5.43%ZFGNZafgen14.20%MiscellaneousCompanyEmployeesShares OutstandingFree FloatOptionableGERNGeron141546.87 million529.92 millionOptionableMRUSMerus17258.69 million56.16 millionOptionableTXMDTherapeuticsMD111.53 million11.39 millionOptionableXENEXenon Pharmaceuticals25175.43 million71.34 millionOptionableZFGNZafgen3837.47 millionN/ANot OptionableMRUS, ZFGN, GERN, XENE, and TXMD HeadlinesSourceHeadlineDiagnosing Diabetes: Not So Simplemedscape.com - November 2 at 7:42 AMDo New Weight Loss Meds Mean the End of Bariatric Surgery?medscape.com - October 6 at 8:53 PMPrader-Willi syndromepharmaphorum.com - August 23 at 8:34 PMThe Omnipod 5 System: Trial Results From ENDO 2021medscape.com - August 4 at 8:12 PMBeta Cells From Stem Cells: Nearing a Cure for Type 1 Diabetes?medscape.com - July 5 at 5:09 PMOral Semaglutide Brings GLP-1s to Primary Caremedscape.com - May 20 at 8:49 PMClinical Trials - Different Phases of the trial News, Research and Latest Updatesmedindia.net - May 20 at 3:49 PMObesity Therapeutic Pipeline Analysis, 2023 Updates | Insights into ... - Digital Journalnews.google.com - May 12 at 2:12 PMWeight Loss and Obesity Management Market Insights With ... - Taiwan Newsnews.google.com - May 11 at 3:06 AMGlobal Methionine Aminopeptidase 2 Market Report 2023 by Trend ... - The Northwestern Examinernews.google.com - May 4 at 6:30 PMWeight Loss and Obesity Management Market May See a Big Move ... - Digital Journalnews.google.com - May 2 at 1:13 PMIronwood Pharmaceuticals: A Promising Outlook for Long-Term ... - Best Stocksnews.google.com - May 2 at 8:13 AMThe Primary Glucose-Lowering Effect of Metformin Resides in the Gut, Not the Circulationmedscape.com - April 29 at 8:09 PMFast Five Quiz: Type 2 Diabetes and Dyslipidemia - Medscape Referencenews.google.com - April 22 at 12:41 AMAnti-Obesity Drugs Market Size, Share, Economic Growth, Emerging ... - Digital Journalnews.google.com - April 20 at 9:32 AMAnti-Obesity Drugs Market Size, Analysis, Share, Research, Business Growth and Forecast to 2031 - openPRnews.google.com - April 14 at 8:21 AMNew ADA Standards: Promoting Healthmedscape.com - April 13 at 7:20 AMNew ADA Standards: Promoting Healthmedscape.com - April 13 at 7:20 AMAnti-Obesity Drugs Market Set to Register a CAGR of 16.10% and ... - GlobeNewswirenews.google.com - April 10 at 12:56 PMGlobal Weight Loss Therapeutics Professional Market 2023 (Exclusive Report) | Future Work Trend by 2030marketwatch.com - April 9 at 10:32 AMAnti-Obesity Drugs Market is expected to rise at A CAGR Of 16.1% during the forecast period 2023 to 2031: Grow - openPRnews.google.com - April 5 at 7:34 AMAnti-Obesity Drugs Market to grow at a CAGR of over 16.1% from 2023 to 2031, reveals Growth Plus Reports - openPRnews.google.com - March 22 at 11:43 AMIndian Anti-Obesity Drug Market 2023 : Projected to Deliver Greater Revenues during the Forecast Period 2028 - openPRnews.google.com - March 1 at 1:17 PMZafgen (ZFGN) Stock Skyrockets on Positive Obesity Drug Resultsthestreet.com - February 26 at 7:51 PMNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCompany DescriptionsGeronNASDAQ:GERNGeron Corporation, a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for myeloid hematologic malignancies. It develops imetelstat, a telomerase inhibitor that is in Phase 3 clinical trials, which inhibits the uncontrolled proliferation of malignant stem and progenitor cells in myeloid hematologic malignancies for the treatment of low or intermediate-1 risk myelodysplastic syndromes and intermediate-2 or high-risk myelofibrosis. The company was incorporated in 1990 and is headquartered in Foster City, California.MerusNASDAQ:MRUSMerus N.V., a clinical-stage immuno-oncology company, engages in the development of antibody therapeutics in the Netherlands. Its bispecific antibody candidate pipeline includes Zenocutuzumab (MCLA-128), which is in a phase 2 clinical trials for the treatment of patients with metastatic breast cancer and castration-resistant prostate cancer, as well as in Phase 1/2 clinical trials for the treatment of solid tumors that harbor Neuregulin 1. The company is also developing MCLA-158, which is in a phase I clinical trial for the treatment of solid tumors; MCLA-145, which is in phase 1 clinical trials for the treatment of solid tumors; MCLA-129, which is in phase 1/2 clinical trials for the treatment of patients with advanced non-small cell lung cancer and other solid tumors; and ONO-4685 that is Phase 1 clinical trial to treat relapsed/refractory T cell lymphoma. In addition, it has collaboration agreement with Betta Pharmaceuticals Co. Ltd for the research and development of stage bispecific antibody candidates include MCLA-129; collaboration with Incyte Corporation for the development of MCLA-145; and collaboration with Gilead Sciences, Inc. to discover novel antibody-based trispecific T-cell engagers. The company was incorporated in 2003 and is headquartered in Utrecht, the Netherlands.TherapeuticsMDNASDAQ:TXMDTherapeuticsMD, Inc. operates as a pharmaceutical royalty company in the United States. It has a license agreement with Mayne Pharma to commercialize the IMVEXXY, BIJUVA, and ANNOVERA prescription prenatal vitamin products sold under the BocaGreenMD and vitaMedMD brand names. The company sells its prescription pharmaceutical products and prenatal vitamin products through wholesale distributors and retail pharmacy distributors. TherapeuticsMD, Inc. was founded in 2008 and is headquartered in Boca Raton, Florida.Xenon PharmaceuticalsNASDAQ:XENEXenon Pharmaceuticals Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline includes XEN496, a Kv7 potassium channel opener that is Phase III clinical trials for the treatment of KCNQ2 developmental and epileptic encephalopathy; and XEN1101, a Kv7 potassium channel opener, which is in Phase II clinical trial for the treatment of epilepsy and other neurological disorders. The company's product candidates also comprise NBI-921352, a selective Nav1.6 sodium channel inhibitor that is in Phase II clinical trials for the treatment of SCN8A developmental and epileptic encephalopathy, and other indications, including adult focal epilepsy. It has a license and collaboration agreement with the Neurocrine Biosciences, Inc. to develop treatments for epilepsy. The company was incorporated in 1996 and is headquartered in Burnaby, Canada.ZafgenNASDAQ:ZFGNZafgen, Inc., a clinical-stage biopharmaceutical company, develops therapies for patients suffering from metabolic diseases comprising type 2 diabetes, Prader-Willi syndrome (PWS), and other metabolically related disorders. The company's lead product candidate is ZGN-1061, a fumagillin-class methionine aminopeptidase 2 (MetAP2) inhibitor administered by subcutaneous injection, which is in Phase 2 clinical trial and profiled for its utility in the treatment of type 2 diabetes and other related metabolic disorders. It also develops ZGN-1258, a MetAP2 inhibitor for treatment of PWS. Zafgen, Inc. was founded in 2005 and is headquartered in Boston, Massachusetts. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.